Zimmer Biomet: Competing against Stryker’s MakoZimmer Biomet (NYSE:ZBH) is also seeking to compete against Stryker in the robot-assisted knee surgery space through its Rosa platform. The Rosa system boasts 2D X-ray and 3D pre-operative planning tools, allowing surgeons to conduct virtual procedures ahead of the actual surgeries — as well as real-time intraoperative data on soft tissue and bone anatomy.
Zimmer Biomet acquired the initial Rosa technology through its roughly $132 million purchase of French robot-assisted surgery firm Medtech in 2016.
The company had nearly 300 Rosa knee systems placed around the world by the end of 2020.
Zimmer Biomet CEO Bryan Hanson said during a Feb. 5 earnings call that Q4 2020 was the strongest quarter yet since the launch of Rosa Knee. “With some of the new launches that we have coming, specifically associated with the knee, I feel pretty confident that 2021 is going to continue to show that kind of resilience and strength for Rosa Knee.”
Zimmer Biomet also has a Rosa spine system and its Rosa One Brain system for neurosurgical procedures.